Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2017/10/09
-
Journal
-
Indian UGC (journal)
-
Refrences16
-
Citations27
-
Rahul Gosain Division of Hematology and Medical Oncology James Graham Brown Cancer Center University of Louisville School of Medicine Louisville Kentucky
-
Amitoj Gill Division of Hematology and Medical Oncology James Graham Brown Cancer Center University of Louisville School of Medicine Louisville Kentucky
-
Jacob Fuqua Department of Medicine University of Louisville School of Medicine Louisville Kentucky ORCID (unauthenticated)
-
Lesley H. Volz Department of Pharmacy James Graham Brown Cancer Center University of Louisville Louisville Kentucky
-
Mika R. Kessans Knable Department of Pharmacy James Graham Brown Cancer Center University of Louisville Louisville Kentucky
-
Ryan Bycroft Department of Pharmacy James Graham Brown Cancer Center University of Louisville Louisville Kentucky
-
Sarah Seger Department of Pharmacy James Graham Brown Cancer Center University of Louisville Louisville Kentucky
-
Rohit Gosain Division of Hematology and Medical Oncology Roswell Park Cancer Institute Buffalo New York
-
Jorge A. Rios Division of Hematology and Medical Oncology The Mark H. Zangmeister Cancer Center Columbus Ohio
-
Ju‐Hsien Chao Division of Hematology and Medical Oncology Texas Transplant Physician Group ‐ Methodist Physicians San Antonio Texas
Abstract
Journal Category
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| A review of hemolytic uremic syndrome in patient targeted with gemcitabine therapy | Cancer |
| 1999 | |
| 10.1007/BF00873232 | ||||
| 10.1002/0470015535 | ||||
| Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura | Kidney International |
| 282 | 2001 |
Drug-induced thrombotic microangiopathy: a systematic review of published reports | Blood Journal |
| 222 | 2015 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy | Blood Cancer Journal |
| 4 | 2023 |
Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition | BMC Nephrology |
| 1 | 2023 |
Chemotherapy-Associated Thrombotic Microangiopathy | Kidney360 |
| 2023 | |
| Beyond Immunosuppression: The Intricate Relationship Between Tacrolimus and Microangiopathy | Cureus | 2023 | ||
| Thrombotic Microangiopathy Syndromes—Common Ground and Distinct Frontiers | Advances in Chronic Kidney Disease |
| 8 | 2022 |
Citations Analysis
The category
Medicine: Medicine (General) 19
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion and was published in 2018. The most recent citation comes from a 2023 study titled Beyond Immunosuppression: The Intricate Relationship Between Tacrolimus and Microangiopathy. This article reached its peak citation in 2020, with 10 citations. It has been cited in 23 different journals, 26% of which are open access. Among related journals, the BMC Nephrology cited this research the most, with 3 citations. The chart below illustrates the annual citation trends for this article.